Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 42Leukemia 34Lymphoma, Large B-Cell, Diffuse 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia, Myeloid, Acute 24Burkitt Lymphoma 19Leukemia, Myelomonocytic, Acute 16Lung Neoplasms 15Leukemia, Monocytic, Acute 15Neuroblastoma 14Leukemia, Megakaryoblastic, Acute 14Leukemia, Erythroblastic, Acute 14Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 13Hodgkin Disease 12Congenital Abnormalities 12Carcinoma, Non-Small-Cell Lung 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Central Nervous System Neoplasms 10Sarcoma 9Myelodysplastic Syndromes 9Anemia, Refractory, with Excess of Blasts 8Small Cell Lung Carcinoma 7Myeloproliferative Disorders 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Neoplasms 6Multiple Myeloma 6Lymphoma, B-Cell, Marginal Zone 6

Interventions

molibresib 1etoposide phosphate 1Platinum 1Etoposide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic NUT Carcinoma × Etoposide × Clear all
NCT04116359 2020-09-28

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Withdrawn

Metastatic NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡